206 related articles for article (PubMed ID: 37725008)
1. Synthetic Heterodimers of Type III Interferon Receptors Require TYK2 for STAT Activation.
Mesev EV; Guare EG; Ploss A; Toettcher JE
J Interferon Cytokine Res; 2023 Sep; 43(9):414-426. PubMed ID: 37725008
[TBL] [Abstract][Full Text] [Related]
2. Pseudorabies Virus Inhibits Type I and Type III Interferon-Induced Signaling via Proteasomal Degradation of Janus Kinases.
Yin Y; Romero N; Favoreel HW
J Virol; 2021 Sep; 95(20):e0079321. PubMed ID: 34379505
[TBL] [Abstract][Full Text] [Related]
3. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
[TBL] [Abstract][Full Text] [Related]
4. Interferon alpha activates NF-kappaB in JAK1-deficient cells through a TYK2-dependent pathway.
Yang CH; Murti A; Valentine WJ; Du Z; Pfeffer LM
J Biol Chem; 2005 Jul; 280(27):25849-53. PubMed ID: 15883164
[TBL] [Abstract][Full Text] [Related]
5. Respirovirus C protein inhibits activation of type I interferon receptor-associated kinases to block JAK-STAT signaling.
Kitagawa Y; Yamaguchi M; Kohno M; Sakai M; Itoh M; Gotoh B
FEBS Lett; 2020 Mar; 594(5):864-877. PubMed ID: 31705658
[TBL] [Abstract][Full Text] [Related]
6. Selective Janus kinase inhibition preserves interferon-λ-mediated antiviral responses.
Schnepf D; Crotta S; Thamamongood T; Stanifer M; Polcik L; Ohnemus A; Vier J; Jakob C; Llorian M; Gad HH; Hartmann R; Strobl B; Kirschnek S; Boulant S; Schwemmle M; Wack A; Staeheli P
Sci Immunol; 2021 May; 6(59):. PubMed ID: 33990378
[TBL] [Abstract][Full Text] [Related]
7. Kinase-deficient forms of Jak1 and Tyk2 inhibit interferon alpha signaling in a dominant manner.
Krishnan K; Pine R; Krolewski JJ
Eur J Biochem; 1997 Jul; 247(1):298-305. PubMed ID: 9249040
[TBL] [Abstract][Full Text] [Related]
8. IFNAR1 and IFNAR2 play distinct roles in initiating type I interferon-induced JAK-STAT signaling and activating STATs.
Shemesh M; Lochte S; Piehler J; Schreiber G
Sci Signal; 2021 Nov; 14(710):eabe4627. PubMed ID: 34813358
[TBL] [Abstract][Full Text] [Related]
9. Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent.
Li Z; Gakovic M; Ragimbeau J; Eloranta ML; Rönnblom L; Michel F; Pellegrini S
J Immunol; 2013 Mar; 190(5):2335-44. PubMed ID: 23359498
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Disrupts Proximal Elements in the JAK-STAT Pathway.
Chen DY; Khan N; Close BJ; Goel RK; Blum B; Tavares AH; Kenney D; Conway HL; Ewoldt JK; Chitalia VC; Crossland NA; Chen CS; Kotton DN; Baker SC; Fuchs SY; Connor JH; Douam F; Emili A; Saeed M
J Virol; 2021 Sep; 95(19):e0086221. PubMed ID: 34260266
[TBL] [Abstract][Full Text] [Related]
11. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer.
Slattery ML; Lundgreen A; Kadlubar SA; Bondurant KL; Wolff RK
Mol Carcinog; 2013 Feb; 52(2):155-66. PubMed ID: 22121102
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses.
Fuchs S; Kaiser-Labusch P; Bank J; Ammann S; Kolb-Kokocinski A; Edelbusch C; Omran H; Ehl S
Eur J Immunol; 2016 Nov; 46(11):2639-2649. PubMed ID: 27615517
[TBL] [Abstract][Full Text] [Related]
13. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha.
Li S; Labrecque S; Gauzzi MC; Cuddihy AR; Wong AH; Pellegrini S; Matlashewski GJ; Koromilas AE
Oncogene; 1999 Oct; 18(42):5727-37. PubMed ID: 10523853
[TBL] [Abstract][Full Text] [Related]
14. Constitutive STAT1 tyrosine phosphorylation in U937 monocytes overexpressing the TYK2 protein tyrosine kinase does not induce gene transcription.
Eilers A; Kanda K; Klose B; Krolewski J; Decker T
Cell Growth Differ; 1996 Jun; 7(6):833-40. PubMed ID: 8780896
[TBL] [Abstract][Full Text] [Related]
15. Beta interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway.
Stancato LF; Sakatsume M; David M; Dent P; Dong F; Petricoin EF; Krolewski JJ; Silvennoinen O; Saharinen P; Pierce J; Marshall CJ; Sturgill T; Finbloom DS; Larner AC
Mol Cell Biol; 1997 Jul; 17(7):3833-40. PubMed ID: 9199317
[TBL] [Abstract][Full Text] [Related]
16. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
[TBL] [Abstract][Full Text] [Related]
17. The Atlantic salmon protein tyrosine kinase Tyk2: molecular cloning, modulation of expression and function.
Sobhkhez M; Hansen T; Iliev DB; Skjesol A; Jørgensen JB
Dev Comp Immunol; 2013 Dec; 41(4):553-63. PubMed ID: 23872231
[TBL] [Abstract][Full Text] [Related]
18. Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2.
Wang F; Barrett JW; Shao Q; Gao X; Dekaban GA; McFadden G
Virology; 2009 Apr; 387(1):136-46. PubMed ID: 19254804
[TBL] [Abstract][Full Text] [Related]
19. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
Solimani F; Meier K; Ghoreschi K
Eur J Immunol; 2021 May; 51(5):1071-1075. PubMed ID: 33675065
[TBL] [Abstract][Full Text] [Related]
20. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2.
Piganis RA; De Weerd NA; Gould JA; Schindler CW; Mansell A; Nicholson SE; Hertzog PJ
J Biol Chem; 2011 Sep; 286(39):33811-8. PubMed ID: 21757742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
